Follicular Lymphoma Treatment in the Modern Era: Survival, Treatment Outcomes, and Identification of High-Risk Subgroups
The treatment of follicular lymphoma is in high demand; therefore, research centers and market players invest considerable sums in R&D.
VANCOUVER, BC, CANADA, April 25, 2022 /EINPresswire.com/ — Follicular lymphoma is the most common type of low-grade non-Hodgkin’s lymphoma and the second most common type of lymphoma. Primary extranodal follicular lymphoma is rare compared to nodular follicular lymphoma involving the gastrointestinal (GI) tract. There has been uncertainty regarding follicular lymphomas due to the heterogeneous presentation and severity in which they present.
According to the current analysis of Emergen research, the Follicular Lymphoma Treatment Market was valued at USD 2.08 billion in 2019 and is expected to reach USD 3.73 billion by 2027, at a CAGR of 7.6%. The global follicular lymphoma treatment market is growing with a lucrative CAGR owing to growing demand for therapy, growing innovation in new drug development, favorable financial support from government, and aid in research and treatment-oriented development. The treatment of follicular lymphoma is in high demand; therefore, research centers and market players invest considerable sums in R&D. Additionally, various treatment options for FL are based primarily on the severity of the symptoms associated with it. Based on various studies, there have been incidences where patients managed with an active surveillance approach have identical survival outcomes to those who receive early treatment.
According to the Leukemia & Lymphoma Society, in 2019, approximately 82,310 new cases of lymphoma and 8,110 and 74,200 cases of Hodgkin’s and non-Hodgkin’s lymphoma (NHL), respectively, were diagnosed in the United States. Additionally, of 30 NHL subtypes, follicular lymphoma contributes about 20-30% of cases making it the most common form. In the western world, the number is equal to 20% of all lymphomas. With new therapies emerging to combat disease, monoclonal antibodies may act more directly than chemotherapeutic agents. This is another area of active research around the world.
For a sample PDF copy of the report, visit @ https://www.emergenresearch.com/request-sample/51
Newly approved drugs and the clinical trial pipeline of follicular lymphoma therapies have a promising future. Additionally, the shift from cytotoxic agents to targeted and immunotherapeutic agents is expected to drive the market. Although follicular lymphoma remains incurable, recently approved immunotherapeutic agents have shown prolonged overall patient survival. Drugs nearing completion and growing awareness among health care providers will together contribute to the increase in demand. After the approval of rituximab, many new drugs appeared to treat follicular lymphoma.
Key Players Featured in the Report:
Bristol Myers Squibb and Company
F. Hoffmann La Roche SA
Johnson and Johnson Services
Merck & Co. Inc.
Major Key Points of the Follicular Lymphoma Treatment Market
Follicular Lymphoma Treatment Market Overview.
Competition in the Follicular Lymphoma Treatment Market.
Follicular Lymphoma Treatment Market, Revenue and Price Trends.
Follicular Lymphoma Treatment Market Analysis by Application.
Company Profiles and Key Figures of the Follicular Lymphoma Treatment Market.
Follicular Lymphoma Treatment Market Dynamics.
For example, obinutuzumab was recently included in the Australian Pharmaceutical Benefits Scheme for application in frontline advanced follicular lymphoma. Clinical results show drastic changes with the emergence of improved first-line therapy in recent years. In the event of a recurrence of the disease, stem cell transplantation may be a treatment option. These benefits are expected to propel the market significantly over the forecast period. Treatment patterns do not differ significantly in Asia from Western countries. The conception of epidemiology is likely to change with better health care. However, stringent drug approval regulatory policies, coupled with the high cost of treatment, remain a major market barrier in low-economy countries.
The North American follicular lymphoma treatment market is expected to dominate the global market. The growth is attributed to the growing demand for first-line therapies, high medical reimbursement facilities, and technological advancements in countries like the United States and Canada.
Combination drug therapy is an upcoming trend in the market. For example, in May 2019, the U.S. Food and Drug Administration (FDA) approved lenalidomide (REVLIMID) in combination with rituximab (RITUXAN) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). and marginal zone lymphoma (MZL).
Research organizations are expected to be the largest segment of the follicular lymphoma treatment market over the forecast period. The growth is due to its wide application in the field of research. Non-Hodgkin’s lymphoma is one of the most common cancers in the world. In recent years, a lot of research has been done to find the most suitable therapy.
Access the full report @ https://www.emergenresearch.com/industry-report/follicular-lymphoma-treatment-market
Emergen research has segmented the global follicular lymphoma treatment market based on treatment, route of administration, end-use and region:
Treatment Outlook (Revenue, USD Million; 2017-2027)
Stem cell transplant
Route of Administration Outlook (Revenue, USD Million; 2017-2027)
End-Use Outlook (Revenue, USD Million; 2017-2027)
Ambulatory care centers
University research institutes
Regional Outlook (Revenue, USD Million; 2017-2027)
North America (United States, Mexico and Canada)
Asia-Pacific (China, Japan, India and Rest of Asia-Pacific)
Europe (UK, France, Germany and Rest of Europe)
Latin America (Brazil and rest of Latin America)
Middle East and Africa (GCC Countries and Rest of Middle East and Africa)
Request customization of this report @ https://www.emergenresearch.com/request-for-customization/51
Report key offerings:
Detailed overview of market dynamics including drivers, restraints, opportunities, challenges and growth prospects
Analysis of major strategic initiatives and competitive landscape, including mergers and acquisitions, joint ventures, collaborations, product launches, brand promotions and partnerships, among others
Comprehensive industry outlook analysis and industry chain analysis
Market forecast based on global, regional and national market analysis
Benchmark of the competitive landscape
In-depth analysis of major market players with their product portfolios, financial positions, unique selling points, market share and size, and a comprehensive overview of their business
Thank you for reading our report. To learn more about the report or for any questions about customizing the report, please contact us. We will ensure that our team provides the necessary assistance and designs your report according to your requirements.
Other related reports published by InsightAce Analytics:
Immunocytokines Market: https://www.emergenresearch.com/industry-report/immunocytokines-market
Medical Grade Tubing Market: https://www.emergenresearch.com/industry-report/medical-grade-tubing-market
Next Generation Ultrasound Systems Market: https://www.emergenresearch.com/industry-report/next-generation-ultrasound-system-market
Follicular Lymphoma Treatment Market https://www.emergenresearch.com/industry-report/follicular-lymphoma-treatment-market
Cancer Imaging Systems Market https://www.emergenresearch.com/industry-report/cancer-imaging-systems-market
Artificial Intelligence (AI) in the Radiology Market https://www.emergenresearch.com/industry-report/artificial-intelligence-in-radiology-market
Molecular Forensics Market https://www.emergenresearch.com/industry-report/molecular-forensics-market
About Emergen Research
At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting firm with an extensive knowledge base on cutting-edge and potentially market-disrupting technologies that are expected to become more prevalent over the next decade.